Prescient Therapeutics Reports Increased Revenue and Net Loss

Prescient Therapeutics Limited (AU:PTX) has released an update.

Prescient Therapeutics Limited reported a 49.8% increase in revenues to $687,577 for the fiscal year ended June 30, 2024, alongside a 17.6% rise in net loss to $8,238,050, with no dividends issued. The company’s net assets decreased significantly due to increased R&D, corporate, and employment expenses, despite an estimated R&D incentive rebate of $3,712,364.

For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.